Headlines about Abeona Therapeutics (NASDAQ:ABEO) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Abeona Therapeutics earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.8891677598582 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of Abeona Therapeutics (NASDAQ ABEO) opened at $16.50 on Monday. Abeona Therapeutics has a 52 week low of $4.05 and a 52 week high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings data on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.05. The company had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.22 million. Abeona Therapeutics had a negative net margin of 2,946.58% and a negative return on equity of 27.69%. equities research analysts predict that Abeona Therapeutics will post -0.6 earnings per share for the current year.

ABEO has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded shares of Abeona Therapeutics from a “sell” rating to a “buy” rating and set a $18.00 target price for the company in a report on Wednesday, November 22nd. SunTrust Banks started coverage on shares of Abeona Therapeutics in a report on Wednesday, November 8th. They issued a “buy” rating and a $26.00 target price for the company. Maxim Group set a $35.00 price objective on shares of Abeona Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 20th. Royal Bank of Canada started coverage on shares of Abeona Therapeutics in a research note on Thursday, September 14th. They set an “outperform” rating and a $23.00 price objective for the company. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $21.00 price objective on shares of Abeona Therapeutics in a research note on Friday, October 6th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $26.10.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/12/18/abeona-therapeutics-abeo-receives-daily-news-sentiment-score-of-0-17.html.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Insider Buying and Selling by Quarter for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.